Tonix Pharmaceuticals (TNXP)
(Delayed Data from NSDQ)
$0.15 USD
0.00 (-1.60%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.14 -0.01 (-5.08%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Tonix Pharmaceuticals Holding Corp falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 8 | 0 | 0 | 0 | 0 |
Cost Of Goods | 5 | 0 | 0 | 0 | 0 |
Gross Profit | 3 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 121 | 112 | 92 | 51 | 29 |
Income After Depreciation & Amortization | -118 | -112 | -92 | -51 | -29 |
Non-Operating Income | 2 | 2 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -117 | -110 | -92 | -50 | -29 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -117 | -110 | -92 | -50 | -29 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -117 | -110 | -92 | -50 | -29 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -114 | -111 | -92 | -50 | -29 |
Depreciation & Amortization (Cash Flow) | 4 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -118 | -112 | -92 | -51 | -29 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.53 | 0.18 | 0.06 | 0.02 | 0.00 |
Diluted EPS Before Non-Recurring Items | -218.85 | -652.96 | -1,658.69 | -3,508.76 | NA |
Diluted Net EPS (GAAP) | -218.85 | -652.96 | -1,658.69 | -3,508.76 | NA |
Fiscal Year end for Tonix Pharmaceuticals Holding Corp falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 2.21 | 2.48 | 3.78 | 3.99 | 0.00 |
Cost Of Goods | 3.37 | 1.66 | 2.37 | 2.37 | 0.00 |
Gross Profit | -1.16 | 0.82 | 1.41 | 1.62 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 76.16 | 22.17 | 28.74 | 29.76 | 29.01 |
Income After SG&A, R&D, and Dept/Amort Expenses | -77.32 | -21.35 | -27.33 | -28.14 | -29.01 |
Non-Operating Income | -1.46 | 6.41 | 0.01 | 0.17 | 0.65 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -78.78 | -14.94 | -27.32 | -27.98 | -28.36 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -78.78 | -14.94 | -27.32 | -27.98 | -28.36 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -78.78 | -14.94 | -27.32 | -27.98 | -28.36 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 4.09 | 2.53 | 0.99 | 0.48 | 0.33 |
Diluted EPS Before Non-Recurring Items | -19.28 | -5.75 | -27.48 | -58.47 | -85.62 |
Diluted Net EPS (GAAP) | -19.28 | -5.75 | 29.07 | -58.47 | -85.62 |